{"pmid":32298145,"title":"The Role of Data Registries in the Time of COVID-19.","text":["The Role of Data Registries in the Time of COVID-19.","On April 1, 2020, the confirmed global burden of COVID-19 was more than 900,000 with 46,413 deaths. Despite worldwide calls for social distancing and containment, the incidence of the disease continues to increase. COVID-19 is a respiratory tract infection caused by the novel coronavirus (SARS-CoV2). Preliminary analyses from the Chinese Center for Disease Control and Prevention indicated an overall case fatality rate (CFR) of 2.3%; however the CFR was higher in older adults (14.8% in those 80+/- years) and 49% of all critical cases. Those with preexisting conditions (cardiovascular disease (CVD), diabetes, chronic respiratory disease, hypertension, and cancer) also had higher CRFs. In the United States, 116 million adults have hypertension, 26 million US adults have diabetes mellitus, 9% have preexisting CVD and may therefore be at greater risk of complications or adverse health outcomes from COVID-19 infection.","Circ Cardiovasc Qual Outcomes","Alger, Heather M","Williams Iv, Joseph H","Walchok, Jason G","Bolles, Michele M","Fonarow, Gregg C","Rutan, Christine","32298145"],"abstract":["On April 1, 2020, the confirmed global burden of COVID-19 was more than 900,000 with 46,413 deaths. Despite worldwide calls for social distancing and containment, the incidence of the disease continues to increase. COVID-19 is a respiratory tract infection caused by the novel coronavirus (SARS-CoV2). Preliminary analyses from the Chinese Center for Disease Control and Prevention indicated an overall case fatality rate (CFR) of 2.3%; however the CFR was higher in older adults (14.8% in those 80+/- years) and 49% of all critical cases. Those with preexisting conditions (cardiovascular disease (CVD), diabetes, chronic respiratory disease, hypertension, and cancer) also had higher CRFs. In the United States, 116 million adults have hypertension, 26 million US adults have diabetes mellitus, 9% have preexisting CVD and may therefore be at greater risk of complications or adverse health outcomes from COVID-19 infection."],"journal":"Circ Cardiovasc Qual Outcomes","authors":["Alger, Heather M","Williams Iv, Joseph H","Walchok, Jason G","Bolles, Michele M","Fonarow, Gregg C","Rutan, Christine"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298145","week":"202016|Apr 13 - Apr 19","doi":"10.1161/CIRCOUTCOMES.120.006766","keywords":["COVID-19","Get With The Guidelines","atrial fibrillation","coronary artery disease","database"],"source":"PubMed","weight":0,"locations":["United States","US"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664266651225292801,"score":8.233237,"similar":[{"pmid":32298251,"title":"Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.","text":["Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.","Since SARS-CoV-2, the novel coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in December 2019 (1), approximately 1.3 million cases have been reported worldwide (2), including approximately 330,000 in the United States (3). To conduct population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in the United States, the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) was created using the existing infrastructure of the Influenza Hospitalization Surveillance Network (FluSurv-NET) (4) and the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET). This report presents age-stratified COVID-19-associated hospitalization rates for patients admitted during March 1-28, 2020, and clinical data on patients admitted during March 1-30, 2020, the first month of U.S. surveillance. Among 1,482 patients hospitalized with COVID-19, 74.5% were aged >/=50 years, and 54.4% were male. The hospitalization rate among patients identified through COVID-NET during this 4-week period was 4.6 per 100,000 population. Rates were highest (13.8) among adults aged >/=65 years. Among 178 (12%) adult patients with data on underlying conditions as of March 30, 2020, 89.3% had one or more underlying conditions; the most common were hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%). These findings suggest that older adults have elevated rates of COVID-19-associated hospitalization and the majority of persons hospitalized with COVID-19 have underlying medical conditions. These findings underscore the importance of preventive measures (e.g., social distancing, respiratory hygiene, and wearing face coverings in public settings where social distancing measures are difficult to maintain)(dagger) to protect older adults and persons with underlying medical conditions, as well as the general public. In addition, older adults and persons with serious underlying medical conditions should avoid contact with persons who are ill and immediately contact their health care provider(s) if they have symptoms consistent with COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html) (5). Ongoing monitoring of hospitalization rates, clinical characteristics, and outcomes of hospitalized patients will be important to better understand the evolving epidemiology of COVID-19 in the United States and the clinical spectrum of disease, and to help guide planning and prioritization of health care system resources.","MMWR Morb Mortal Wkly Rep","Garg, Shikha","Kim, Lindsay","Whitaker, Michael","O'Halloran, Alissa","Cummings, Charisse","Holstein, Rachel","Prill, Mila","Chai, Shua J","Kirley, Pam D","Alden, Nisha B","Kawasaki, Breanna","Yousey-Hindes, Kimberly","Niccolai, Linda","Anderson, Evan J","Openo, Kyle P","Weigel, Andrew","Monroe, Maya L","Ryan, Patricia","Henderson, Justin","Kim, Sue","Como-Sabetti, Kathy","Lynfield, Ruth","Sosin, Daniel","Torres, Salina","Muse, Alison","Bennett, Nancy M","Billing, Laurie","Sutton, Melissa","West, Nicole","Schaffner, William","Talbot, H Keipp","Aquino, Clarissa","George, Andrea","Budd, Alicia","Brammer, Lynnette","Langley, Gayle","Hall, Aron J","Fry, Alicia","32298251"],"abstract":["Since SARS-CoV-2, the novel coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in December 2019 (1), approximately 1.3 million cases have been reported worldwide (2), including approximately 330,000 in the United States (3). To conduct population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in the United States, the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) was created using the existing infrastructure of the Influenza Hospitalization Surveillance Network (FluSurv-NET) (4) and the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET). This report presents age-stratified COVID-19-associated hospitalization rates for patients admitted during March 1-28, 2020, and clinical data on patients admitted during March 1-30, 2020, the first month of U.S. surveillance. Among 1,482 patients hospitalized with COVID-19, 74.5% were aged >/=50 years, and 54.4% were male. The hospitalization rate among patients identified through COVID-NET during this 4-week period was 4.6 per 100,000 population. Rates were highest (13.8) among adults aged >/=65 years. Among 178 (12%) adult patients with data on underlying conditions as of March 30, 2020, 89.3% had one or more underlying conditions; the most common were hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%). These findings suggest that older adults have elevated rates of COVID-19-associated hospitalization and the majority of persons hospitalized with COVID-19 have underlying medical conditions. These findings underscore the importance of preventive measures (e.g., social distancing, respiratory hygiene, and wearing face coverings in public settings where social distancing measures are difficult to maintain)(dagger) to protect older adults and persons with underlying medical conditions, as well as the general public. In addition, older adults and persons with serious underlying medical conditions should avoid contact with persons who are ill and immediately contact their health care provider(s) if they have symptoms consistent with COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html) (5). Ongoing monitoring of hospitalization rates, clinical characteristics, and outcomes of hospitalized patients will be important to better understand the evolving epidemiology of COVID-19 in the United States and the clinical spectrum of disease, and to help guide planning and prioritization of health care system resources."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Garg, Shikha","Kim, Lindsay","Whitaker, Michael","O'Halloran, Alissa","Cummings, Charisse","Holstein, Rachel","Prill, Mila","Chai, Shua J","Kirley, Pam D","Alden, Nisha B","Kawasaki, Breanna","Yousey-Hindes, Kimberly","Niccolai, Linda","Anderson, Evan J","Openo, Kyle P","Weigel, Andrew","Monroe, Maya L","Ryan, Patricia","Henderson, Justin","Kim, Sue","Como-Sabetti, Kathy","Lynfield, Ruth","Sosin, Daniel","Torres, Salina","Muse, Alison","Bennett, Nancy M","Billing, Laurie","Sutton, Melissa","West, Nicole","Schaffner, William","Talbot, H Keipp","Aquino, Clarissa","George, Andrea","Budd, Alicia","Brammer, Lynnette","Langley, Gayle","Hall, Aron J","Fry, Alicia"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298251","week":"202016|Apr 13 - Apr 19","doi":"10.15585/mmwr.mm6915e3","source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["United States","United States","USA","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664266651182301184,"score":286.00183},{"pmid":32255507,"title":"COVID-19 And Older Adults: What We Know.","text":["COVID-19 And Older Adults: What We Know.","SARS-CoV-2, a novel virus that causes COVID-19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease. A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and chronic kidney disease are placed on angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Studies have shown that these medications upregulate the ACE-2 receptor, the very receptor which the SARS-CoV-2 virus uses to enter host cells, which puts older adults at a further increased risk of infection. In this review, we discuss the transmission, symptomatology, mortality, and possible treatments for this infection, as they relate to older adults. This article is protected by copyright. All rights reserved.","J Am Geriatr Soc","Shahid, Zainab","Kalayanamitra, Ricci","McClafferty, Brendan","Kepko, Douglas","Ramgobin, Devyani","Patel, Ravi","Aggarwal, Chander Shekher","Vunnam, Rama Rao","Sahu, Nitasa","Bhatt, Dhirisha","Jones, Kirk","Golamari, Reshma","Jain, Rohit","32255507"],"abstract":["SARS-CoV-2, a novel virus that causes COVID-19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease. A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and chronic kidney disease are placed on angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Studies have shown that these medications upregulate the ACE-2 receptor, the very receptor which the SARS-CoV-2 virus uses to enter host cells, which puts older adults at a further increased risk of infection. In this review, we discuss the transmission, symptomatology, mortality, and possible treatments for this infection, as they relate to older adults. This article is protected by copyright. All rights reserved."],"journal":"J Am Geriatr Soc","authors":["Shahid, Zainab","Kalayanamitra, Ricci","McClafferty, Brendan","Kepko, Douglas","Ramgobin, Devyani","Patel, Ravi","Aggarwal, Chander Shekher","Vunnam, Rama Rao","Sahu, Nitasa","Bhatt, Dhirisha","Jones, Kirk","Golamari, Reshma","Jain, Rohit"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32255507","week":"202015|Apr 06 - Apr 12","doi":"10.1111/jgs.16472","keywords":["COVID-19","Coronavirus","Mortality","Older Adults","SARS-CoV-2"],"source":"PubMed","locations":["American"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Transmission","Diagnosis","Treatment"],"weight":1,"_version_":1663450393559957504,"score":281.08496},{"pmid":32240123,"title":"Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020.","text":["Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020.","On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic (1). As of March 28, 2020, a total of 571,678 confirmed COVID-19 cases and 26,494 deaths have been reported worldwide (2). Reports from China and Italy suggest that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions (3,4). U.S. older adults, including those aged >/=65 years and particularly those aged >/=85 years, also appear to be at higher risk for severe COVID-19-associated outcomes; however, data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported (5). As of March 28, 2020, U.S. states and territories have reported 122,653 U.S. COVID-19 cases to CDC, including 7,162 (5.8%) for whom data on underlying health conditions and other known risk factors for severe outcomes from respiratory infections were reported. Among these 7,162 cases, 2,692 (37.6%) patients had one or more underlying health condition or risk factor, and 4,470 (62.4%) had none of these conditions reported. The percentage of COVID-19 patients with at least one underlying health condition or risk factor was higher among those requiring intensive care unit (ICU) admission (358 of 457, 78%) and those requiring hospitalization without ICU admission (732 of 1,037, 71%) than that among those who were not hospitalized (1,388 of 5,143, 27%). The most commonly reported conditions were diabetes mellitus, chronic lung disease, and cardiovascular disease. These preliminary findings suggest that in the United States, persons with underlying health conditions or other recognized risk factors for severe outcomes from respiratory infections appear to be at a higher risk for severe disease from COVID-19 than are persons without these conditions.","MMWR Morb Mortal Wkly Rep","32240123"],"abstract":["On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic (1). As of March 28, 2020, a total of 571,678 confirmed COVID-19 cases and 26,494 deaths have been reported worldwide (2). Reports from China and Italy suggest that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions (3,4). U.S. older adults, including those aged >/=65 years and particularly those aged >/=85 years, also appear to be at higher risk for severe COVID-19-associated outcomes; however, data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported (5). As of March 28, 2020, U.S. states and territories have reported 122,653 U.S. COVID-19 cases to CDC, including 7,162 (5.8%) for whom data on underlying health conditions and other known risk factors for severe outcomes from respiratory infections were reported. Among these 7,162 cases, 2,692 (37.6%) patients had one or more underlying health condition or risk factor, and 4,470 (62.4%) had none of these conditions reported. The percentage of COVID-19 patients with at least one underlying health condition or risk factor was higher among those requiring intensive care unit (ICU) admission (358 of 457, 78%) and those requiring hospitalization without ICU admission (732 of 1,037, 71%) than that among those who were not hospitalized (1,388 of 5,143, 27%). The most commonly reported conditions were diabetes mellitus, chronic lung disease, and cardiovascular disease. These preliminary findings suggest that in the United States, persons with underlying health conditions or other recognized risk factors for severe outcomes from respiratory infections appear to be at a higher risk for severe disease from COVID-19 than are persons without these conditions."],"journal":"MMWR Morb Mortal Wkly Rep","date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240123","week":"202014|Mar 30 - Apr 05","doi":"10.15585/mmwr.mm6913e2","source":"PubMed","locations":["USA","Italy","China","United States"],"countries":["China","United States","Italy"],"countries_codes":["CHN|China","USA|United States","ITA|Italy"],"topics":["Diagnosis"],"weight":1,"_version_":1663352135553646592,"score":245.91383},{"pmid":32283499,"pmcid":"PMC7144598","title":"Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.","text":["Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.","BACKGROUND AND AIMS: COVID-19 is already a pandemic. Emerging data suggest an increased association and a heightened mortality in patients of COVID-19 with comorbidities. We aimed to evaluate the outcome in hypertensive patients with COVID-19 and its relation to the use of renin-angiotensin system blockers (RASB). METHODS: We have systematically searched the medical database up to March 27, 2020 and retrieved all the published articles in English language related to our topic using MeSH key words. RESULTS: From the pooled data of all ten available Chinese studies (n = 2209) that have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients. Although the emerging data hints to an increase in mortality in COVID-19 patients with known hypertension, diabetes and CVD, it should be noted that it was not adjusted for multiple confounding factors. Harm or benefit in COVID-19 patients receiving RASB has not been typically assessed in these studies yet, although mechanistically and plausibly both, benefit and harm is possible with these agents, given that COVID-19 expresses to tissues through the receptor of angiotensin converting enzyme-2. CONCLUSION: Special attention is definitely required in patients with COVID-19 with associated comorbidities including hypertension, diabetes and established CVD. Although the role of RASB has a mechanistic equipoise, patients with COVID-19 should not stop these drugs at this point of time, as recommended by various world organizations and without the advice of health care provider.","Diabetes Metab Syndr","Singh, Awadhesh Kumar","Gupta, Ritesh","Misra, Anoop","32283499"],"abstract":["BACKGROUND AND AIMS: COVID-19 is already a pandemic. Emerging data suggest an increased association and a heightened mortality in patients of COVID-19 with comorbidities. We aimed to evaluate the outcome in hypertensive patients with COVID-19 and its relation to the use of renin-angiotensin system blockers (RASB). METHODS: We have systematically searched the medical database up to March 27, 2020 and retrieved all the published articles in English language related to our topic using MeSH key words. RESULTS: From the pooled data of all ten available Chinese studies (n = 2209) that have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients. Although the emerging data hints to an increase in mortality in COVID-19 patients with known hypertension, diabetes and CVD, it should be noted that it was not adjusted for multiple confounding factors. Harm or benefit in COVID-19 patients receiving RASB has not been typically assessed in these studies yet, although mechanistically and plausibly both, benefit and harm is possible with these agents, given that COVID-19 expresses to tissues through the receptor of angiotensin converting enzyme-2. CONCLUSION: Special attention is definitely required in patients with COVID-19 with associated comorbidities including hypertension, diabetes and established CVD. Although the role of RASB has a mechanistic equipoise, patients with COVID-19 should not stop these drugs at this point of time, as recommended by various world organizations and without the advice of health care provider."],"journal":"Diabetes Metab Syndr","authors":["Singh, Awadhesh Kumar","Gupta, Ritesh","Misra, Anoop"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283499","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.dsx.2020.03.016","keywords":["Angiotensin-converting enzyme inhibitors","Angiotensin-receptor blockers","COVID-19","Comorbidities","Hypertension"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664182200831049728,"score":233.34256},{"pmid":32201335,"title":"Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","text":["Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.","J Am Coll Cardiol","Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A","32201335"],"abstract":["The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems."],"journal":"J Am Coll Cardiol","authors":["Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201335","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jacc.2020.03.031","keywords":["cardiovascular therapy","coronavirus","health system"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1663352133651529728,"score":231.5402}]}